Sivia Capital Partners LLC Acquires Shares of 6,509 Illumina, Inc. $ILMN

Key Points

• Sivia Capital Partners LLC has made a new investment in Illumina, Inc., purchasing 6,509 shares valued at approximately $621,000.
• Illumina recently reported quarterly earnings of $1.19 per share, surpassing analysts' expectations, but its revenue was down by 4.8% year-over-year.
• Analysts have mixed ratings on Illumina, with a consensus rating of "Hold" and an average price target of $123.06.

Sivia Capital Partners LLC bought a new stake in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 6,509 shares of the life sciences company's stock, valued at approximately $621,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in ILMN. Rise Advisors LLC increased its position in Illumina by 173.6% during the 1st quarter. Rise Advisors LLC now owns 353 shares of the life sciences company's stock valued at $28,000 after purchasing an additional 224 shares during the period. Rakuten Securities Inc. increased its position in Illumina by 290.3% during the 1st quarter. Rakuten Securities Inc. now owns 363 shares of the life sciences company's stock valued at $29,000 after purchasing an additional 270 shares during the period. Center for Financial Planning Inc. acquired a new stake in Illumina during the 1st quarter valued at approximately $33,000. Fourth Dimension Wealth LLC acquired a new stake in Illumina during the 4th quarter valued at approximately $40,000. Finally, PFS Partners LLC increased its position in Illumina by 400.0% during the 1st quarter. PFS Partners LLC now owns 500 shares of the life sciences company's stock valued at $40,000 after purchasing an additional 400 shares during the period. Institutional investors and hedge funds own 89.42% of the company's stock.

Illumina Stock Up 2.1%

Shares of ILMN traded up $2.16 during trading hours on Thursday, reaching $103.03. The stock had a trading volume of 1,137,167 shares, compared to its average volume of 1,315,924. Illumina, Inc. has a 12 month low of $68.70 and a 12 month high of $156.66. The firm has a 50-day simple moving average of $99.71 and a 200 day simple moving average of $88.91. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.66. The company has a market capitalization of $15.84 billion, a price-to-earnings ratio of 13.04, a P/E/G ratio of 2.27 and a beta of 1.43.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its earnings results on Thursday, July 31st. The life sciences company reported $1.19 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.02 by $0.17. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The company had revenue of $1.06 billion for the quarter, compared to analysts' expectations of $1.12 billion. During the same period last year, the business earned $0.36 EPS. Illumina's quarterly revenue was down 4.8% compared to the same quarter last year. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. Equities research analysts predict that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Scotiabank cut Illumina from a "sector outperform" rating to a "sector perform" rating and set a $125.00 price target on the stock. in a report on Friday, July 11th. Canaccord Genuity Group increased their price target on Illumina from $99.00 to $105.00 and gave the stock a "hold" rating in a report on Friday, August 1st. Royal Bank Of Canada set a $124.00 price target on Illumina in a report on Tuesday, September 2nd. Daiwa America cut Illumina from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 12th. Finally, Robert W. Baird increased their price target on Illumina from $84.00 to $105.00 and gave the stock a "neutral" rating in a report on Monday, July 28th. Six analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $123.06.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.